Cancer's sweet tooth becomes a target


By Andy Coghlan A DRUG that blocks the way cancer cells generate energy could lead to a new class of cancer treatments. The first human trial of the drug, published this week, is reported to have extended the lives of four people with an aggressive form of brain cancer. The result is preliminary, but it suggests that, as an approach, tackling “cancer metabolism” is sound. “We are still a long way from a treatment, but this opens the window on drugs that target cancer metabolism,” says Evangelos Michelakis of the University of Alberta in Edmonton, Canada,
  • 首页
  • 游艇租赁
  • 电话
  • 关于我们